Literature DB >> 10944591

A systematic review of the role of human papilloma virus (HPV) testing within a cervical screening programme: summary and conclusions.

J Cuzick1, P Sasieni, P Davies, J Adams, C Normand, A Frater, M van Ballegooijen, E van den Akker-van Marle.   

Abstract

A systematic review of the available evidence on the role of HPV testing in cervical screening has been published by the Health Technology Assessment Committee of the UK Department of Health. The review summarized relevant data on testing methods, natural history, and prevalence of the virus in different disease groups. Cost-effectiveness modelling was undertaken. Ten major conclusions were reached and are reported here. The key conclusions were that HPV testing was more sensitive than cytology, but that there were concerns about specificity, especially in young women. The increased sensitivity led to a recommendation that HPV testing be introduced on a pilot basis for women with borderline and mild smears. HPV testing has great potential as a primary screening test, but large trials are needed to properly evaluate this application and to determine if its introduction can reduce invasive cancer rates. There is an urgent need to undertake a large trial of HPV testing in conjunction with other new technologies (liquid-based cytology and computer-assisted cytology reading) to determine the best way to integrate them into ongoing screening programmes. A range of issues including the age to start and stop screening, the appropriate screening interval, the role of self-sampling for HPV testing and the choice of primary test (HPV and/or cytology) require further evaluation. Copyright 2000 Cancer Research Campaign.

Entities:  

Mesh:

Year:  2000        PMID: 10944591      PMCID: PMC2363499          DOI: 10.1054/bjoc.2000.1375

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  32 in total

1.  HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer.

Authors:  T C Wright; L Denny; L Kuhn; A Pollack; A Lorincz
Journal:  JAMA       Date:  2000-01-05       Impact factor: 56.272

2.  Should cervical cytologic testing be augmented by cervicography or human papillomavirus deoxyribonucleic acid detection?

Authors:  R Reid; M D Greenberg; A Lorincz; A B Jenson; C R Laverty; M Husain; Y Daoud; B Zado; T White; D Cantor
Journal:  Am J Obstet Gynecol       Date:  1991-06       Impact factor: 8.661

3.  Prospective seroepidemiologic study of human papillomavirus infection as a risk factor for invasive cervical cancer.

Authors:  J Dillner; M Lehtinen; T Björge; T Luostarinen; L Youngman; E Jellum; P Koskela; R E Gislefoss; G Hallmans; J Paavonen; M Sapp; J T Schiller; T Hakulinen; S Thoresen; M Hakama
Journal:  J Natl Cancer Inst       Date:  1997-09-03       Impact factor: 13.506

4.  The MISCAN simulation program for the evaluation of screening for disease.

Authors:  J D Habbema; G J van Oortmarssen; J T Lubbe; P J van der Maas
Journal:  Comput Methods Programs Biomed       Date:  1985-05       Impact factor: 5.428

Review 5.  Adenocarcinomas of the uterine cervix: the epidemiology of an increasing problem.

Authors:  S K Kjaer; L A Brinton
Journal:  Epidemiol Rev       Date:  1993       Impact factor: 6.222

6.  Management of women with mild dyskaryosis. Cytological surveillance avoids overtreatment.

Authors:  M I Shafi
Journal:  BMJ       Date:  1994-09-03

7.  Human papillomavirus testing by hybrid capture appears to be useful in triaging women with a cytologic diagnosis of atypical squamous cells of undetermined significance.

Authors:  J T Cox; A T Lorincz; M H Schiffman; M E Sherman; A Cullen; R J Kurman
Journal:  Am J Obstet Gynecol       Date:  1995-03       Impact factor: 8.661

8.  The presence of persistent high-risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease: natural history up to 36 months.

Authors:  A J Remmink; J M Walboomers; T J Helmerhorst; F J Voorhorst; L Rozendaal; E K Risse; C J Meijer; P Kenemans
Journal:  Int J Cancer       Date:  1995-05-04       Impact factor: 7.396

9.  Association between high-risk HPV types, HLA DRB1* and DQB1* alleles and cervical cancer in British women.

Authors:  J Cuzick; G Terry; L Ho; J Monaghan; A Lopes; P Clarkson; I Duncan
Journal:  Br J Cancer       Date:  2000-04       Impact factor: 7.640

10.  Human papillomavirus status in the prediction of high-grade cervical intraepithelial neoplasia in patients with persistent low-grade cervical cytological abnormalities.

Authors:  C S Herrington; M F Evans; N F Hallam; F M Charnock; W Gray; J D McGee
Journal:  Br J Cancer       Date:  1995-01       Impact factor: 7.640

View more
  15 in total

1.  High risk HPV testing following treatment for cervical intraepithelial neoplasia.

Authors:  M Molloy; R Comer; P Rogers; M Dowling; P Meskell; K Asbury; M O'Leary
Journal:  Ir J Med Sci       Date:  2015-12-21       Impact factor: 1.568

2.  Revisiting time to translation: implementation of evidence-based practices (EBPs) in cancer control.

Authors:  Shahnaz Khan; David Chambers; Gila Neta
Journal:  Cancer Causes Control       Date:  2021-01-04       Impact factor: 2.506

Review 3.  What we could do now: molecular pathology of gynaecological cancer.

Authors:  C S Herrington
Journal:  Mol Pathol       Date:  2001-08

Review 4.  The causal relation between human papillomavirus and cervical cancer.

Authors:  F X Bosch; A Lorincz; N Muñoz; C J L M Meijer; K V Shah
Journal:  J Clin Pathol       Date:  2002-04       Impact factor: 3.411

5.  comparison of two commercial assays for detection of human papillomavirus (HPV) in cervical scrape specimens: validation of the Roche AMPLICOR HPV test as a means to screen for HPV genotypes associated with a higher risk of cervical disorders.

Authors:  Maaike A P C van Ham; Judith M J E Bakkers; Gonneke K Harbers; Wim G V Quint; Leon F A G Massuger; Willem J G Melchers
Journal:  J Clin Microbiol       Date:  2005-06       Impact factor: 5.948

6.  Prevalence of human papillomavirus in university young women.

Authors:  Maria T Montalvo; Ismelda Lobato; Hilda Villanueva; Celia Borquez; Daniela Navarrete; Juan Abarca; Gloria M Calaf
Journal:  Oncol Lett       Date:  2011-04-06       Impact factor: 2.967

7.  Assessing 10-Year Safety of a Single Negative HPV Test for Cervical Cancer Screening: Evidence from FOCAL-DECADE Cohort.

Authors:  Anna Gottschlich; Dirk van Niekerk; Laurie W Smith; Lovedeep Gondara; Joy Melnikow; Darrel A Cook; Marette Lee; Gavin Stuart; Ruth E Martin; Stuart Peacock; Eduardo L Franco; Andrew Coldman; Mel Krajden; Gina Ogilvie
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-10-20       Impact factor: 4.254

8.  Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women.

Authors:  C Clavel; M Masure; J P Bory; I Putaud; C Mangeonjean; M Lorenzato; P Nazeyrollas; R Gabriel; C Quereux; P Birembaut
Journal:  Br J Cancer       Date:  2001-06-15       Impact factor: 7.640

9.  Factors associated with cervical cancer screening uptake among Inuit women in Nunavik, Quebec, Canada.

Authors:  Helen Cerigo; Francois Coutlée; Eduardo L Franco; Paul Brassard
Journal:  BMC Public Health       Date:  2013-05-03       Impact factor: 3.295

10.  Attitudes towards HPV testing: a qualitative study of beliefs among Indian, Pakistani, African-Caribbean and white British women in the UK.

Authors:  K McCaffery; S Forrest; J Waller; M Desai; A Szarewski; J Wardle
Journal:  Br J Cancer       Date:  2003-01-13       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.